Short Interest in iSpecimen Inc. (NASDAQ:ISPC) Decreases By 56.2%

iSpecimen Inc. (NASDAQ:ISPC) was the target of a large decrease in short interest in March. As of March 31st, there was short interest totalling 34,900 shares, a decrease of 56.2% from the March 15th total of 79,700 shares. Based on an average daily trading volume, of 803,300 shares, the short-interest ratio is currently 0.0 days. Approximately 4.2% of the company’s stock are sold short.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in iSpecimen stock. Bridgeway Capital Management LLC bought a new stake in iSpecimen Inc. (NASDAQ:ISPC) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 21,800 shares of the company’s stock, valued at approximately $58,000. Bridgeway Capital Management LLC owned 2.27% of iSpecimen at the end of the most recent reporting period. Hedge funds and other institutional investors own 13.62% of the company’s stock.

iSpecimen Trading Down 6.4 %

Shares of NASDAQ ISPC traded down $0.09 during mid-day trading on Friday, reaching $1.24. The company had a trading volume of 32,030 shares, compared to its average volume of 420,485. The firm has a 50 day simple moving average of $1.46 and a two-hundred day simple moving average of $2.87. iSpecimen has a 52-week low of $1.02 and a 52-week high of $11.80. The stock has a market cap of $1.19 million, a P/E ratio of -0.06 and a beta of 1.77.

iSpecimen (NASDAQ:ISPC) last issued its quarterly earnings data on Monday, April 14th. The company reported ($6.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.00) by ($2.28). iSpecimen had a negative return on equity of 139.25% and a negative net margin of 91.66%. The firm had revenue of $1.48 million for the quarter, compared to analysts’ expectations of $2.98 million.

iSpecimen Company Profile

iSpecimen Inc provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers.